Table 2.
Summary Characteristics of Eligible Studies Assessing Treatment Adherence or Persistence
| Study | Country | Clinic Type | Study Design | Methodology | Patients | Drug | Regimen | Planned Frequency of Visits |
|---|---|---|---|---|---|---|---|---|
| Angermann 2019 | Austria | Tertiary | Retrospective observational | Quantitative | 841 | NR | PRN | NR |
| Bobykin 2014 | Russia | NR | Retrospective observational | Mixed | 6 | RBZ | PRN | 4 wks |
| Boulanger-Scemama 2015 | France | Tertiary | Retrospective + telephone survey | Mixed | 60 | RBZ | PRN | 4 wks |
| Boyle 2018 | Australia | Mixed | Cross-sectional survey | Qualitative | 6 | NR | NR | NR |
| Curtis 2012 | United States | NR | Retrospective database | Quantitative | 284 380 | RBZ/BEV/PEG | NR | NR |
| Droege 2013 | Germany | Tertiary | Cross-sectional survey | Qualitative | 77 | RBZ | PRN | 4 wks |
| Ehlken 2018 | Germany | Tertiary | Retrospective observational | Mixed | 466 | RBZ/BEV/AFL | PRN | 4 wks |
| Ehlken 2018a | Germany | Mixed | Retrospective + Prospective | Mixed | 362 | RBZ or BEV | PRN or fixed | 4 wks |
| Heimes 2016 | Germany | NR | Retrospective observational | Mixed | 72 | RBZ | PRN | NR |
| Holz 2015 | Multinational | NR | Retrospective observational | Quantitative | 1514 | RBZ | NR | NR |
| Husler 2013 | Switzerland | Mixed | Cross-sectional survey | Qualitative | 28 | RBZ | NR | NR |
| Jansen 2018 | United States | Local | Self-administered questionnaire | Qualitative | NR | NR | NR | NR |
| Kim 2017 | South Korea | Tertiary | Retrospective observational | Quantitative | 64 | RBZ or BEV | PRN | 4 to 12 wks (8–24 wks if patient refuses additional treatment) |
| Krivosic 2017 | France | NR | Retrospective observational | Quantitative | 163 | NR | NR | NR |
| Kruger Falk 2013 | Denmark | Tertiary | Retrospective observational | Mixed | 399 | RBZ | PRN | 4 to 6 wks (12–24 weeks if no signs of disease activity) |
| Lad 2014 | United States | NR | Retrospective database | Quantitative | 459.237 | RBZ or BEV | NR | NR |
| Massamba 2015 | France | Tertiary | Prospective cohort | Quantitative | 29 | RBZ | PRN | 4 wks |
| McGrath 2013 | Australia | Local | Retrospective + telephone survey | Mixed | 85 | RBZ | T&E | 4–8 wks |
| Nunes 2010 | Brazil | Tertiary | Retrospective + phone interview | Mixed | 19 | BEV | NR | NR |
| Obeid 2018 | United States | Local | Retrospective observational | Quantitative | 2003 | NR | NR | NR |
| Oishi 2011 | Japan | Tertiary | Retrospective + phone interview | Mixed | 86 | RBZ or PEG | PRN | 4–8 wks |
| Ozturk 2018 | United Kingdom | Tertiary | Retrospective observational | Mixed | 21 | AFL | Fixed | 8 wks |
| Polat 2017 | Turkey | NR | Retrospective + telephone survey | Mixed | 125 | RBZ | PRN | 4 wks |
| Ramakrishnan 2020 | United States | Mixed | Secondary analysis of RCT | Quantitative | 1178 | RBZ or BEV | PRN or monthly | 4 wks |
| Rasmussen 2013 | Denmark | Tertiary | Retrospective + telephone survey | Mixed | 381 | RBZ | PRN | 4 wks (8–12 wks if no signs of disease activity) |
| Rasmussen 2017 | Denmark | Tertiary | Retrospective observational | Quantitative | 269 | RBZ or AFL | PRN | 4–6 wks |
| Sii 2018 | United Kingdom | Cross-sectional survey | Qualitative | 53 | RBZ (assumed) | PRN | 4–16 wks | |
| Subhi 2017 | Denmark | Tertiary | Retrospective observational | Quantitative | 59 | RBZ or AFL | PRN | 4 wks (ranibizumab), 8 wks (aflibercept) |
| Varano 2015 | Multinational | NR | Cross-sectional survey | Qualitative | 143 | NR | NR | NR |
| Vaze 2014 | Australia | Local | Retrospective observational | Qualitative | 105 | RBZ | NR | NR |
| Westborg 2018 | Sweden | NR | Retrospective observational | Quantitative | 472 | RBZ or AFL | PRN, T&E, or fixed | NR |
| Wintergerst 2018 | Germany | Tertiary | Retrospective + telephone survey | Mixed | 55 | NR | NR | NR |
AFL = aflibercept; BEV = bevacizumab; NR = not reported; PEG = pegaptanib; PRN = pro re nata; RBZ = ranibizumab; RCT = randomized controlled trial; T&E = treat-and-extend.